Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
301 studies found for:    "Mesothelioma"
Show Display Options
RSS Create an RSS feed from your search for:
"Mesothelioma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Peritoneal Malignant Mesothelioma;   Pleural Biphasic Mesothelioma;   Pleural Epithelioid Mesothelioma;   Pleural Malignant Mesothelioma;   Pleural Sarcomatoid Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
2 Completed Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
3 Active, not recruiting
Has Results
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Conditions: Pleural Mesothelioma;   Peritoneal Mesothelioma
Intervention: Drug: IMC-A12
4 Terminated Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Conditions: Epithelioid Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatoid Mesothelioma;   Stage II Pleural Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IV Pleural Mesothelioma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Tivantinib
5 Terminated Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Conditions: Mesothelioma;   Pleural Mesothelioma
Interventions: Drug: Pemetrexed;   Drug: Cisplatin
6 Completed
Has Results
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Localized Malignant Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Intervention: Drug: cediranib maleate
7 Not yet recruiting Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma;   Pleural Mesothelioma
Interventions: Drug: Concurrent Durvalumab;   Drug: Maintenance Durvalumab
8 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
9 Completed Gefitinib in Treating Patients With Malignant Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
10 Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
11 Recruiting A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Conditions: Pleural Mesothelioma;   Peritoneal Mesothelioma
Intervention: Drug: tremelimumab plus MEDI4736
12 Completed
Has Results
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis
13 Withdrawn AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Biological: rilotumumab;   Drug: cisplatin;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis
14 Completed
Has Results
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: belinostat;   Other: laboratory biomarker analysis
15 Active, not recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelioid Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Pemetrexed Disodium;   Other: Placebo
16 Recruiting Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Conditions: Advanced Peritoneal Malignant Mesothelioma;   Advanced Pleural Malignant Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Solid Neoplasm;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pleural Mesothelioma;   Thymoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium;   Other: Pharmacological Study
17 Recruiting Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Advanced Pleural Malignant Mesothelioma;   HLA-A*0201 Positive Cells Present;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pleural Mesothelioma
Interventions: Biological: Aldesleukin;   Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
18 Completed
Has Results
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Localized Malignant Mesothelioma;   Recurrent Malignant Mesothelioma
Interventions: Other: laboratory biomarker analysis;   Drug: pazopanib hydrochloride
19 Recruiting Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Conditions: Malignant Pleural Mesothelioma;   Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Methotrexate;   Drug: Gemcitabine;   Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire
20 Completed Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Imatinib Mesylate;   Drug: Pemetrexed;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years